In a London court filing, AstraZeneca argued that Sheldon would be violating a non-compete agreement, which he was paid more than $774,000 in shares to sign in 2021, Bloomberg reported.
Sheldon worked at AstraZeneca for more than 18 years. He resigned earlier this month, effective immediately, according to Law360.
According to the Bloomberg report, GSK poached Sheldon and another senior dealmaker to boost its cancer therapies and other drugs pipeline.
Sheldon was tasked with identifying late-stage deal opportunities.
AstraZeneca previously headed to court to protect its interests after a senior executive left for a close rival. In 2017 it sued former executive Luke Miels who also moved to GSK.
AstraZeneca and GSK settled in court, with Miels taking a “gardening leave” until joining GSK in September 2017.
However, according to The Times in London, Miels accused Soriot of threatening him over his visa during the resignation dispute.
Price Action: GSK shares are down 2.52% at $34.37, and AZN stock is up 0.90% at $67.34 on the last check Wednesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.